Goldman Sachs Group Inc Dbv Technologies S.A. Transaction History

Goldman Sachs Group Inc

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$0.75 - $0.95 $24,303 - $30,784	-32,405 Reduced 69.23%	14,400 $10,000
Q4 2023 Feb 13, 2024	BUY	$0.7 - $1.33 $22,683 - $43,098	32,405 Added 225.03%	46,805 $44,000
Q3 2023 May 14, 2024	SELL	$1.3 - $1.88 $42,126 - $60,921	-32,405 Reduced 69.23%	14,400 $19,000
Q2 2022 May 14, 2024	SELL	$1.15 - $3.25 $37,265 - $105,316	-32,405 Reduced 69.23%	14,400 $37,000
Q3 2021 Nov 10, 2021	BUY	$4.71 - $5.92 $67,824 - $85,248	14,400 New	14,400 $71,000

3.2K

Ticker DBVT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,776,992
Market Cap $88.3M
Description
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in 4 to 11 years of age children, adolescents...

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

Stay updated on Goldman Sachs Group Inc with notifications on news.